Science News About Treatments

Scientists have synthesized a molecule with a unique profile of highly specific pain-relieving properties and demonstrated its efficacy in mice.

An individualized program of follow-up treatment with electroconvulsive therapy (ECT) combined with an antidepressant was effective in preventing relapse in patients 60 years and older who had had a successful initial course of treatment for severe depression.

A chemical byproduct, or metabolite, created as the body breaks down likely holds the secret to its rapid antidepressant action .

On March 17, 2016, NIMH hosts a Facebook Q&A on electroconvulsive therapy with expert Dr. Sarah Lisanby.

Is mobile mental health research the next frontier for smartphones? Based on Dr. Patricia Areán’s pioneering BRIGHTEN study, research via smartphone app is already a reality.

Coordinated Specialty Care for First Episode Psychosis is Cost Effective

On October 16, the Centers for Medicare and Medicaid Services announced support for a new treatment for first episode psychosis called coordinated specialty care (CSC). This decision means more clinics may be able to offer CSC and it may become more readily available.

Researchers find antipsychotic use among older adults increases with age despite known health risks. In 2010, more than 3/4 of seniors receiving an antipsychotic prescription had no documented clinical psychiatric diagnosis during the year. In addition, among those who did have a diagnosed mental disorder and/or dementia, nearly half of the oldest patients had dementia, regardless of FDA warnings that antipsychotics increase mortality in people with dementia.

New research shows that a team-based, coordinated specialty care treatment plan produces better outcomes than typical community care for people with first episode psychosis. Investigators also found that treatment is most effective for people who receive care soon after psychotic symptoms begin.

NIMH, NIH, and the National Institute of Justice are collaborating on a 4-year, $6.8 million study called Suicide Prevention for at-Risk Individuals in Transition or “SPIRIT.” The study focuses on the high-risk individuals who are transitioning from jail to community. SPIRIT is NIMH’s first major investment in suicide prevention in the justice system.

View the archived webinars with NIMH experts and grantees, which focus on training, research, and methodology

Boys are more likely than girls to receive an antipsychotic prescription regardless of age, according to a new study published in JAMA Psychiatry.

Many patients with first-episode psychosis receive medications that do not meet guidelines. A study finds that almost 40 % of people with first-episode psychosis in community mental health clinics across the country might benefit from medication treatment changes.

Many patients with psychosis develop health risks associated with premature death early in the course of their mental illness, researchers have found.

A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of – and ahead of – its other antidepressant effects.

A groundbreaking study will help researchers learn more about treating people with suicidal thoughts. Nearly 20,000 patients will be able to enroll in the trial. One of the treatments being tested was developed with the help of other patients

Many patients with psychosis develop health risks associated with premature death early in the course of their mental illness, researchers have found.

NIMH Twitter Chat on Depression and the Development of Novel Medications

Treatment adherence is a problem among people with schizophrenia, who may not take medications because they don’t perceive its need or benefit, don’t like the side effects, or forget. To combat this issue, long-acting injectable medications are administered every 2-4 weeks. But are the new forms of these drugs better than the old ones?

NIMH scientist Dr. Jane Pearson appeared on NPR’s Science Friday to discuss the latest findings in suicide prevention research.

On August 13, 2013, Carlos A. Zarate, M.D., from the National Institute of Mental Health will give a live presentation titled “Ketamine & Next Generation Therapies,” where he will discuss his research on novel medications for treatment-resistant depression and bipolar disorder at the Brain and Behavior Research Foundation.

On Tuesday, July 23, the National Association of Broadcasters (NAB) launched “OK2Talk,” a mental health awareness campaign to increase understanding and awareness about mental health in youth. The campaign includes television and radio ads in English and Spanish that feature teens and young adults opening up about their experiences with mental health.

Improving care for depression in low-income communities -- places where such help is frequently unavailable or hard to find -- provides greater benefits to those in need when community groups such as churches and even barber shops help lead the planning process, according to a new study.

Want to know how the latest findings in neuroscience research go from bench to bedside? NIMH and Science/AAAS partnered to produce an informative webinar on translating neurobiological research into treatments.

HHS Secretary Kathleen Sebelius discusses state of U.S. mental health care, commemorates JFK’s speech on the topic 50 years ago.

Ketamine-like agent lifts depression briefly in treatment-resistant patients, with few side effects.

Among couples in which one partner was diagnosed as having posttraumatic stress disorder (PTSD), participation in disorder-specific couple therapy resulted in decreased PTSD symptom severity and increased patient relationship satisfaction, compared with couples who were placed on a wait list for the therapy, according to a study in the August 15 issue of JAMA, a theme issue on violence and human rights.

Biomarkers identified in research on a fast-acting antidepressant can signal who will respond to the medication and are providing clues to how it works to lift depression.

HIV-positive children older than 1 year who were treated after showing moderate HIV-related symptoms did not experience greater cognitive or behavior problems compared to peers treated when signs of their infection were still mild, according to a study funded by the National Institutes of Health.

Children with autism spectrum disorder (ASD) who attend regular education classes may be more likely to improve their social skills if their typically developing peers are taught how to interact with them than if only the children with ASD are taught such skills. According to a study funded by the National Institutes of Health, a shift away from more commonly used interventions that focus on training children with ASD directly may provide greater social benefits for children with ASD.

Rats exposed to an antidepressant just before and after birth showed substantial brain abnormalities and behaviors, in a study funded by the National Institutes of Health.

An extract of the herb St. Johns Wort and a standard antidepressant medication both failed to outdo a placebo in relieving symptoms of minor depression in a clinical trial comparing the three. The results of this study, consistent with earlier research, do not in support the use of medications for mild depression.

A study in mice has pinpointed a pivotal new player in triggering the rapid antidepressant response produced by ketamine. By deactivating a little-known enzyme, the drug takes the brakes off rapid synthesis of a key growth factor thought to lift depression, say researchers supported by the National Institutes of Health.

Targeting the core social deficits of autism spectrum disorders (ASD) in early intervention programs yielded sustained improvements in social and communication skills even in very young children who have ASD, according to a study funded by the National Institute of Mental Health (NIMH), part of the National Institutes of Health. The study was published online July 28, 2010, in the Journal of Child Psychology and Psychiatry.

People with treatment-resistant bipolar disorder experienced relief from symptoms of depression in as little as 40 minutes after an intravenous dose of the anesthetic medication ketamine in a preliminary study; while the patient group was small, this work adds to evidence that compounds in the class to which ketamine belongs have potential as rapid and effective medications for depression, including bipolar depression.

Overall, only about half of Americans diagnosed with major depression in a given year receive treatment for it, and even fewer—about one fifth—receive treatment consistent with current practice guidelines, according to data from nationally representative surveys supported by NIMH. Among the ethnic/racial groups surveyed, African Americans and Mexican Americans had the lowest rates of use of depression care; all groups reported higher use of past-year psychotherapy vs. medication for depression.

Children with autism who receive a high intensity developmental behavioral intervention starting by age 18–30 months show major improvements in IQ, language, adaptive behavior, and severity of their diagnosis, according to an NIMH-funded study.

Numerous studies have suggested that depression runs in families. Children of depressed parents are 2–3 times as likely to develop depression as compared to children who do not have a family history of the disorder. Other studies have shown that remission of depression in mothers is associated with improvements in psychiatric symptoms in their children. Despite all signs encouraging mothers to prioritize their own mental health, many suffer from untreated depression while managing treatment for their children’s emotional or behavioral problems.

Most children with autism spectrum disorders (ASD) seem to have trouble engaging in everyday social interactions. They may seem to have no reaction to other people or may respond atypically when others show anger or affection. Their own facial expressions, tone of voice, and body language may not match what they are saying, making it difficult for others to respond appropriately. Such barriers to communication can isolate children with ASD from their peers.

The National Institute of Mental Health (NIMH) is launching a large-scale research project to explore whether using early and aggressive treatment, individually targeted and integrating a variety of different therapeutic approaches, will reduce the symptoms and prevent the gradual deterioration of functioning that is characteristic of chronic schizophrenia.

A new 4-minute video from the National Institute of Mental Health provides an overview for the general public on the symptoms, impact, and treatment of depression. The video is available for viewing by individuals or can be used by community groups or in health care offices to inform viewers about depression and its consequences, and the critical importance of seeking treatment.

Citalopram, a medication commonly prescribed to children with autism spectrum disorders (ASD), was no more effective than a placebo at reducing repetitive behaviors, according to researchers funded by the National Institute of Mental Health (NIMH) and other NIH institutes. The study was published in the June 2009 issue of Archives of General Psychiatry.

The 10th annual Brain Awareness Week (BAW), a science and health education fair held in various locations across the United States, teaches fifth through eighth grade students about the brain. In Washington, D.C., it will take place March 16-20, 2009, at the National Museum of Health and Medicine at Walter Reed Army Medical Center. Several institutes from the National Institutes of Health will provide interactive exhibits and lectures focusing on brain health and neuroscience on March 18th and 19th.

A therapy that shows promise in preventing HIV infection could significantly reduce the risk of HIV infection among high-risk groups, but the cost may be substantial unless drug costs can be reduced, according to a study published online ahead of print February 4, 2009, in Clinical Infectious Diseases.

NIMH recently funded Kim Gratz, Ph.D., University of Mississippi Medical Center, and colleagues to continue to test a new group therapy to help women with borderline personality disorder reduce self-harm behaviors and to improve functioning.

Two new grants funded by NIMH will focus on novel and innovative approaches to treating children who have attention deficit hyperactivity disorder (ADHD).

A new NIMH-funded study will help guide the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in children with autism spectrum disorders (ASD).

For the first time, researchers show that preventive treatment with an antidepressant medication or talk therapy can significantly reduce the risk or delay the start of depression following an acute stroke, according to a study funded by the National Institute of Mental Health (NIMH), part of the National Institutes of Health. These findings differ from past studies attempting to prevent poststroke depression. The study appears in the May 28, 2008, issue of the Journal of the American Medical Association.

Reviews of the current research on psychosocial and behavioral therapies, or psychotherapies, for children and adolescents found a number of well established and probably efficacious treatments for many mental disorders. For example, six were probably efficacious for anxiety disorders, and two were well established for attention deficit hyperactivity disorder (ADHD), according to scientists funded by NIMH and the National Institute on Drug Abuse, divisions of the National Institutes of Health.

A new grant funded by NIMH will develop an intervention designed to help people with serious mental illness (SMI) quit smoking. The addiction is very common among people with SMI, and contributes significantly to deteriorating health and higher costs for care. But it is difficult to treat among people with SMI because they require a tailored approach that is incorporated into their existing mental health treatment.

A 20-week group therapy program focusing on cognitive behavioral and skills training, when used in conjunction with usual care, helped reduce symptoms of borderline personality disorder and improve overall functioning, reported NIMH-funded researchers.

Experts on trauma-related research and medical practices from around the world recently identified five principles to guide mental health care efforts immediately or shortly after a mass trauma, such as a natural disaster or terrorist attack. In a related commentary, NIMH scientist Farris Tuma, Sc.D., MHS, discusses how these principles may help determine effective mental health care for large numbers of people following an emergency, and how best to deliver it. The article and commentary were published in the Winter 2007 issue of Psychiatry: Interpersonal and Biological Processes.

Chemically blocking an enzyme in a specific area in the brain’s cortex, or outer mantle, erased a long-term memory of an aversive event that rats had learned, a study funded in part by NIMH has found.

NIMH-funded researchers recently completed a pilot study showing that an Internet-based, self-managed cognitive behavioral therapy (CBT) can help reduce symptoms of post-traumatic stress disorder (PTSD) and depression, with effects that last after treatment has ended.

Family-based treatment for adolescent bulimia nervosa (FBT-BN) is more effective than an individual-based therapy called supportive psychotherapy (SPT) in helping teens overcome bulimia according to an NIMH-funded study.

As young people with mental health disorders transition from adolescence to adulthood, they frequently face new and difficult challenges such as the loss of state-issued benefits like Medicaid and foster care, or loss of family-based insurance coverage.

Two new studies provide additional details on best practices for treating people with bipolar disorder, a sometimes debilitating illness marked by severe mood swings between depression and mania.

NIMH-funded scientists have developed a new high-speed technique for imaging brain activity and used it to pinpoint a circuit signal in rats that may be at the crossroads of depression — a possible “final common pathway” where different causes of, and treatments for, the disorder appear to converge.

A variation in a gene called GRIK4 appears to make people with depression more likely to respond to the medication citalopram (Celexa) than are people without the variation, a study by the National Institute of Mental Health (NIMH), part of the National Institutes of Health, has found.

A new study has revealed more about how the medication ketamine, when used experimentally for depression, relieves symptoms of the disorder in hours instead of the weeks or months it takes for current antidepressants to work.

Most children treated in a variety of ways for attention deficit hyperactivity disorder (ADHD) showed sustained improvement after three years in a major follow-up study funded by the National Institutes of Health’s (NIH) National Institute of Mental Health (NIMH).

Switching to or adding cognitive therapy (CT) after a first unsuccessful attempt at treating depression with an antidepressant medication is generally as effective as switching to or adding another medication, but remission may take longer to achieve

Patients taking medications to treat bipolar disorder are more likely to get well faster and stay well if they receive intensive psychotherapy, according to results from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), funded by the National Institutes of Health’s (NIH) National Institute of Mental Health (NIMH).

For depressed people with bipolar disorder who are taking a mood stabilizer, adding an antidepressant medication is no more effective than a placebo (sugar pill), according to results published online on March 28, 2007 in the New England Journal of Medicine.

Principal investigators of NIMHs four large-scale clinical trials presented study results and their implications at the National Advisory Mental Health Council meeting on September 15, 2006.

An overall assessment of the nation’s largest real-world study of treatment-resistant depression suggests that a patient with persistent depression can get well after trying several treatment strategies, but his or her odds of beating the depression diminish as additional treatment strategies are needed.

Patients with treatment-resistant depression had a modest chance of becoming symptom-free when they tried different treatment strategies after two or three failed treatments, according to results from the nation’s largest real-world study of depression.

A long-term, large-scale study has found that an Internet-based intervention program may prevent some high risk, college-age women from developing an eating disorder.

Dialectical Behavior Therapy (DBT) reduced suicide attempts by half compared with other types of psychotherapy available in the community in patients with borderline personality disorder, an NIMH-funded study has found.

Most Seasonal Affective Disorder (SAD) symptoms stem from daily body rhythms that have gone out-of-sync with the sun, a NIMH-funded study has found.

A national clinical trial comparing clozapine with other new-generation antipsychotic medications for the treatment of chronic schizophrenia has shown that people who switched to clozapine from their first medication because it failed to manage symptoms adequately were twice as likely to continue treatment as patients who switched to other antipsychotic medications.

Results of the nation’s largest depression study show that one in three depressed patients who previously did not achieve remission using an antidepressant became symptom-free with the help of an additional medication and one in four achieved remission after switching to a different antidepressant.

People age 70 and older who continued taking the antidepressant that helped them to initially recover from their first episode of depression were 60 percent less likely to experience a new episode of depression over a two-year study period than those who stopped taking the medication, according to a study funded by the National Institute of Mental Health (NIMH), part of the National Institutes of Health.

Findings from an NIMH research program on bipolar disorder provide much needed long-term data on the chronic, recurrent course of the disorder, and begin the work of building an evidence-base on the best treatments for those with the disorder.

Initial results of the nation’s largest clinical trial for depression have helped clinicians to track “real world” patients who became symptom-free and to identify those who were resistant to the initial treatment.

Recent suicide attempters treated with cognitive therapy were 50 percent less likely to try to kill themselves again within 18 months than those who did not receive the therapy, report researchers supported by the National Institutes of Health’s (NIH) National Institute of Mental Health (NIMH) and the Center for Disease Control and Prevention (CDC).

Children and adolescents with Obsessive Compulsive Disorder (OCD) respond best to a combination of both psychotherapy and an antidepressant, a major clinical trial has found.

A clinical trial of 439 adolescents with major depression has found a combination of medication and psychotherapy to be the most effective treatment.

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS).

Adolescents and teens with emotional and behavioral problems will receive treatment as part of a new study in eight of the poorest Appalachian counties in Eastern Tennessee.

Treatment with medication or psychotherapy reduced depressive symptoms in women from minority populations, according to research funded by the National Institute of Mental Health (NIMH).

In a new approach to research on minor depression, the National Institutes of Health (NIH) has launched a four-year study to determine the safety and effectiveness of St. Johns wort, a common herbal supplement, and citalopram, a standard antidepressant, compared to placebo.

Whether it’s a widely prescribed medication or a placebo, a successful treatment for depression must trigger a common pattern of brain activity changes, suggests a team of researchers funded by the National Institute of Mental Health.